

Ellen A. Ronnen, M.D.

HOME:

31 Franklyn Place
Metuchen, NJ 08840
732 494-5650
eronnen@gmail.com

OFFICE:

Regional Cancer Care Associates LLC
Central Jersey Division
J2 Brier Hill Court, East Brunswick, NJ 08816
454 Elizabeth Avenue, Suite 240, Somerset, NJ 08873
732-390-7750
Fax: 732-390-7725

Education and Training

- 8/90-5/94 **Yale University**, New Haven, CT 06520
BA Biology received in 5/94
- 8/95-6/99 **Albert Einstein College of Medicine**, 1300 Morris Park Avenue, Bronx, NY 10461
MD received in 6/99
- 7/99-6/02 **New York University Medical Center**, 560 First Avenue, New York, NY 10016 and
Bellevue Hospital, 27th St and First Avenue, New York, NY 10016
Residency in Internal Medicine
- 7/02-6/03 **New York University Medical Center**, 560 First Avenue, New York, NY 10016 and
Bellevue Hospital, 27th St and First Avenue, New York, NY 10016
Chief Residency in Internal Medicine
- 7/03-6/06 **Memorial Sloan-Kettering Cancer Center**, 1275 York Avenue, New York, NY
10021
Fellowship in Medical Oncology and Hematology

Professional Positions:

- 7/2006-Present **Regional Cancer Care Associates LLC: Private Practice**
(Formerly; Central Jersey Oncology Center, PA)
Brier Hill Court, East Brunswick, NJ 08816

Publications

Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, DeLuka JK, Schwartz L, Bacik J, Motzer RJ. A Phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma, *Investigational New Drugs*. 2006 Nov;24(6):543-6.

Ronnen EA, Kondagunta GV, Ginsberg MS, Russo P, Motzer RJ. Long-term response for metastatic renal cell carcinoma with sunitinib: A case report, *Urology*. 2006 Sep;68(3):672.e19-20. Epub 2006 Sep 18.

Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib, *Journal of Clinical Oncology*. 2006 Mar 20;24(9):e14.

Ronnen EA, Kondagunta GV, Bacik J, Marion S, Bajorin DF, Sheinfeld J, Bosl GJ, Motzer RJ. Incidence of late relapse germ cell tumor and outcome to salvage chemotherapy, *Journal of Clinical Oncology*. 2005 Oct 1;23(28):6999-7004.

Ronnen EA Chapters on Renal Cell Carcinoma; Hodgkin's disease. In: Danso M, Basch E, eds. *Hematology and Oncology Pearls*. 1st Ed., Kolam Publishing; 2005.

Ronnen EA, Motzer RJ. Signal transduction inhibitors in renal cell carcinoma. In: Bukowski R, Novick A, eds. *Clinical Management of Renal Tumors*. 1st Ed. Totowa, NJ: Humana Press; 2005, in press.

Ronnen EA, O'Reilly EM. Literature reviews in Colorectal Cancer: Index & Reviews. 2005.

Abstracts

Ronnen EA, Kondagunta GV, Fischer P, Lau C, Ginsberg MS, Baum M, Kim ST, Chen I, Baum CM, Motzer RJ. A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC). *Proceedings of ASCO 2006*, Vol 24, #4537, p.

Ronnen EA, Kondagunta GV, Bacik J, Marion S, Bajorin DF, Sheinfeld J, Bosl GJ, Motzer RJ. Treatment outcome and incidence for late relapse of germ cell tumor patients: The Memorial Sloan-Kettering Cancer Center experience. *Proceedings of ASCO 2005*, Vol 23 (16S), #4522, p383.

Presentations

A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC). Poster Discussion at the Annual Meeting of the American Society of Clinical Oncology, 2006, Atlanta, GA.

Novel agents in the treatment of renal cell carcinoma. Grand Rounds at Memorial Sloan Kettering Cancer Center, January 2006.

Ellen A. Ronnen, MD

Treatment outcome and incidence for late relapse of germ cell tumor (GCT) patients (pts): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Poster Discussion at the Annual Meeting of the American Society of Clinical Oncology, 2005, Orlando, FL.

Prior Research Experience

- 1999 Albert Einstein College of Medicine, Department of Obstetrics and Gynecology
Mentor: David Barad, MD.
- Investigated literature on relation of inhibin levels and occurrence of amenorrhea in runners, wrote accepted research proposal for Institutional Review Board.
- 1994-1995 Stanford University, Department of Cardiothoracic Surgery
Mentor: Carol Clayberger, Ph.D
Analyzed MHC peptides and their role in preventing allograft rejection in the rodent ear-heart model.
- 1994 Yale University School of Medicine, Department of Pathology
Mentor: Jon Morrow, MD, Ph.D.
Conducted experiments to determine SH3 domain containing proteins that bind to BIZII spectrin.

Professional Licensure

- 2008 Diplomate-Hematology
American Board of Internal Medicine
- 2006 State of New Jersey Medical License (25MA08099000)
Diplomate-Medical Oncology
American Board of Internal Medicine
- 2002 Diplomate-Internal Medicine
American Board of Internal Medicine
- 2012 Re-certified Diplomate-Internal Medicine
- 2001 Doctor of Medicine and Surgery- New York State License Number 220234

Hospital Appointments

- 2006-Present Attending Physician
Robert Wood Johnson University Hospital, New Brunswick, NJ
- 2007-Present Attending Physician
St. Peter's University Hospital, New Brunswick, NJ

Rev: 1/2015